预约演示
更新于：2024-12-24
Aprocitentan
更新于：2024-12-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2024-03-19), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14Br2N6O4S |
InChIKeyDKULOVKANLVDEA-UHFFFAOYSA-N |
CAS号1103522-45-7 |
关联
14
项与 Aprocitentan 相关的临床试验NCT05196399
A Single-center, Open-label, Randomized, Two-way Crossover Phase 1 Study to Compare the Single-dose Pharmacokinetics of Different Tablet Formulations of Aprocitentan in Healthy Subjects
The main purpose is to study the pharmacokinetics of aprocitentan (ACT-132577) using 2 different tablet formulations. The clinical pharmacology data will be used to determine bioequivalence of 2 different tablet formulations.
开始日期2022-02-02 |
申办/合作机构 |
NCT04252495
An Open-label Phase 1 Study to Investigate the Effect of Moderate Hepatic Impairment Due to Liver Cirrhosis on the Pharmacokinetics of a Single Dose of 25 mg Aprocitentan
This is a prospective, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).
开始日期2020-06-26 |
申办/合作机构 |
NCT04281342
Prospective, Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, 4-way Crossover Phase 1 Study to Assess the Effect of Multiple Therapeutic and Supratherapeutic Doses of Aprocitentan on the QT Interval Duration in Healthy Subjects
To demonstrate that multiple-dose administration of oral therapeutic and supratherapeutic doses of aprocitentan do not have a clinically relevant effect on the QT interval.
开始日期2020-01-14 |
申办/合作机构 |
100 项与 Aprocitentan 相关的临床结果
登录后查看更多信息
100 项与 Aprocitentan 相关的转化医学
登录后查看更多信息
100 项与 Aprocitentan 相关的专利（医药）
登录后查看更多信息
56
项与 Aprocitentan 相关的文献（医药）2024-11-01·Heart (British Cardiac Society)
Diagnosis and management of resistant hypertension
Review
作者: Kreutz, Reinhold ; Cho, Myeong-Chan ; Camafort, Miguel
Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic. To be diagnosed as resistant hypertension, maintaining adherence to therapy is required along with confirmation of blood pressure levels above target by out-of-office blood pressure measurements and exclusion of secondary causes of hypertension. The key management points of this condition include lifestyle changes such as reduced sodium and alcohol intake, regular physical activity, weight loss and discontinuation of substances that can interfere with blood pressure control. It is also recommended that current treatment be rationalised, including single pill combination treatment where antihypertensive drugs should be provided at the maximum tolerated dose. It is further recommended that current drugs be replaced with a more appropriate and less difficult treatment regimen based on the patient’s age, ethnicity, comorbidities and risk of drug–drug interactions. The fourth line of treatment for patients with resistant hypertension should include mineralocorticoid receptor antagonists such as spironolactone, as demonstrated in the PATHWAY-2 trial and meta-analyses. Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.
2024-09-01·Expert Review of Cardiovascular Therapy
Options for patients with out-of-control blood pressure: after all avenues have been exhausted
Review
作者: Tomlinson, Brian ; Zeng, Weiwei
INTRODUCTION:
Uncontrolled hypertension is the leading risk factor for global mortality. Most hypertensive patients can be controlled with standard medication combinations, but some may not respond adequately to ≥3 or even to ≥5 antihypertensive agents.
AREAS COVERED:
In this review, we summarize the recent literature on difficult-to-treat hypertension identified by a Medline search, and we discuss the options for fourth line and subsequent therapy.
EXPERT OPINION:
It is essential to confirm resistant hypertension with out-of-office blood pressure measurements and to consider lifestyle factors, adherence to medication and secondary causes of hypertension. When true resistant hypertension is confirmed and blood pressure is not controlled with an optimal triple combination, preferably as a fixed dose combination tablet, spironolactone is usually recommended as the fourth medication. Comorbid conditions should be treated as appropriate with sodium-glucose-cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, sacubitril-valsartan or finerenone. Renal denervation appears to be a useful addition to overcome some of the problems of medication adherence. The endothelin antagonist aprocitentan may be a final option in some countries. Of the drugs in development, the RNA based therapeutics that inhibit angiotensinogen synthesis appear to be some of the most promising.
2024-07-03·Future Cardiology
Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists
Review
作者: Heidari Nejad, Sayeh ; Azzam, Omar ; Schlaich, Markus P
Resistant hypertension is characterized by the inability of guideline-recommended triple combination therapy to control blood pressure (BP) to target. It is associated with a significantly increased risk of adverse outcomes. Despite abundant preclinical evidence supporting the critical role of the endothelin pathway in resistant hypertension (RH), clinical implementation of endothelin antagonists for the treatment of hypertension was hindered by various factors. Recently, the novel dual endothelin-receptor antagonist aprocitentan was tested in individuals with resistant hypertension in the PRECISION trial and provided compelling evidence supporting both short and longer-term safety and clinically meaningful and sustained BP lowering efficacy. These findings resulted in the recent regulatory approval of aprocitentan by the FDA. Aprocitentan may be a particularly useful antihypertensive option for individuals with advanced age, chronic kidney disease, and albuminuria.
97
项与 Aprocitentan 相关的新闻（医药）2024-12-20
Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company’s outstanding debt and extend the operational cash runway Allschwil, Switzerland – December 20, 2024Idorsia Ltd (SIX: IDIA) today provided an update on the ongoing exclusive negotiations for the global rights to aprocitentan. On November 27, 2024, the company announced that it had entered exclusive negotiations with an undisclosed party for global rights to aprocitentan that resulted in an exclusivity fee of USD 35 million paid in early December. At that time, the company was targeting signing an agreement before the end of 2024 and closing in early 2025, with more details to be shared should a final agreement be signed. In addition, the company announced plans to streamline its business to reduce costs and restructure its outstanding debt. Idorsia believes signing will not be achieved in 2024. Negotiations with the undisclosed party continue, however the company cannot guarantee that an agreement can be reached. As a result, the company is considering options to extend the company’s operational cash runway to bridge to a potential binding offer, as well as all strategic options. André C. Muller, CEO of Idorsia, commented: “Signing the agreement for aprocitentan is a crucial first step to ensure the future of Idorsia. Based on our current liquidity forecasts, there are additional prerequisites to allow the company to continue to operate, which include the completion of the recently announced company restructuring; the restructuring of the company’s outstanding debt, including the 2025 and 2028 convertible bonds; and raising additional funding. As a result of these constraints and the delay to the completion of the aprocitentan agreement, we are also considering all strategic options beyond a deal for aprocitentan.” Convertible Bond restructuringThe company has issued two convertible bonds which rank pari-passu, the first with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share, maturing on January 17, 2025 (CB 2025), the second with a nominal value of CHF 600 million and a conversion price of CHF 31.54, maturing on August 4, 2028, although investors may request redemption of the bonds as of August 4, 2026 (CB 2028). Given the near-term maturity and the inability of the company to repay the bonds at this time, an extension to the CB 2025 is required whatever the outcome of the ongoing negotiation regarding the rights to aprocitentan. The company is in discussions with certain holders of the CB 2025 and the CB 2028 to amend the terms of both instruments following an extension of the CB 2025. Company restructuringFollowing a consultation process with employee representatives at headquarters a reduction of approximately 250 positions globally is anticipated. The company has already begun the implementation of the restructuring and expects the cost reduction to be largely effective by Q2 2025. Additional fundingIdorsia expects to close 2024 with cash of at least CHF 70 million including the USD 35 million exclusivity fee. The company could end 2024 with cash of around CHF 100 million, should an additional deal close in the coming days. Should the potential agreement for the rights to aprocitentan conclude in a timely manner, in-line with the upfront payment anticipated in the non-binding offer, and subject to the CB 2025 restructuring, Idorsia would be funded until mid-2025. The company is diligently seeking additional funding of at least CHF 200 million to extend its operational cash runway into at least 2026. Updated guidance for 2024For 2024 – excluding unforeseen events and broadly in-line with previously issued guidance – the company expects QUVIVIQ net sales of around CHF 55 million, SG&A expenses of around CHF 265 million, R&D expense of around CHF 130 million for Idorsia-led pipeline assets, leading to non-GAAP operating expenses around CHF 400 million. This performance would result in an Idorsia-led business non-GAAP operating loss of around CHF 350 million. The company expects a US GAAP operating loss for 2024 of around CHF 260 million which includes a one-off benefit of CHF 125 million from the agreement with Viatris on selatogrel and cenerimod and an estimated restructuring charge of CHF 10 million. Guidance for 2024 in CHF million* Idorsia-led business Partner-led business Global BusinessREVENUE 55 50 105COGS -10 -30 -40SG&A OPEX -265 – -265R&D OPEX -130 0 -130Non-GAAP EBIT -350 20 -330D&A -30 – -30SBC -15 – -15Other -10 125 115US-GAAP EBIT -405 145 -260 *Excluding unforeseen events Notes to the editor About the 2025 convertible bondOn July 17, 2018, Idorsia raised CHF 200 million through the issuance of convertible bonds to fund the Phase 3 development of aprocitentan, clazosentan, lucerastat and daridorexant, as well as the early-stage and preclinical pipeline. The bonds initially had a term of six years, maturing on July 17, 2024. On May 6, 2024, a bondholders’ meeting approved modifications to the terms of the convertible bonds to, among others, amend the conversion price to CHF 6.00 per Idorsia share (from CHF 33.95) and extend the maturity date by six months to January 17, 2025. About the 2028 convertible bondOn August 4, 2021, Idorsia raised CHF 600 million through the issuance of convertible bonds to support the commercial product launches in several key markets and to fund the further development of the late-stage pipeline. The bonds have a conversion price of CHF 31.54 and a term of seven years, maturing on August 4, 2028. Investors may request redemption of the bonds as of the 5th anniversary of the settlement date. About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contactAndrew C. WeissSenior Vice President, Head of Investor Relations & Corporate CommunicationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 (0)58 844 10 10investor.relations@idorsia.commedia.relations@idorsia.com www.idorsia.com The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment
Press Release PDF
财报
2024-11-29
Company enters into exclusive negotiations with an undisclosed party for global rights to aprocitentan
Company to streamline the business, resulting in cost containment – consequently, approximately 270 positions globally could become redundant
Company plans to restructure its outstanding debt
November 27, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. Idorsia will receive an exclusivity fee of USD 35 million, which extends Idorsia’s cash runway into 2025. The potential agreement under discussion could include an upfront payment, additional milestone payments, and tiered royalties on sales in return for the transfer of global rights to aprocitentan and certain team members from Idorsia.
André C. Muller, CEO of Idorsia, commented: “I am pleased to announce that we made an important step to reaching a potential agreement for the global rights to aprocitentan. We are targeting signing before the end of 2024 and closing in early 2025, more details will be shared should a final agreement be signed. This is a first and crucial step in our plan to put Idorsia in a financially sustainable position and on the road towards profitability.”
André continued: “In addition, we are implementing initiatives which include cost-containment measures, and steps to restructure our outstanding debt. I am confident that our plan is achievable within the next few months, and that will allow us to shift our focus back to our products. Simply put, we must contain our ambition and restrict our investments until we are generating the revenues from both proprietary and partnered products that will sustain our activities.”
To reach sustainable profitability, the company must focus its efforts, reducing the number of active projects in research and development and preparing some for out-licensing. Consequently, a reduction of the number of employees is envisaged. Depending on the outcome of a consultation process initiated with employee representatives at headquarters, approximately 270 positions globally could become redundant, mainly in Research & Development and support functions at headquarters. Idorsia’s key global functions will continue to be headquartered in Allschwil, Switzerland. The company is committed to minimizing the number of potential redundancies through natural attrition, retirement, transfer along with aprocitentan, and other measures. As part of the ongoing aprocitentan discussions, the company is looking for ways to mitigate the social impact. The company expects some employees could potentially be offered the opportunity to continue to pursue their efforts to make aprocitentan a success should a final agreement be reached. Upon completion of the consultation process, Idorsia intends to conclude restructuring by the end of 2024, with the cost reduction becoming fully effective by Q2 2025.
Aprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the US. On June 27, 2024, aprocitentan was granted market authorization by the European Commission as JERAYGO™.
Idorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients.
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize innovative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has an experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.
The content above comes from the network. if any infringement, please contact us to modify.
上市批准引进/卖出
2024-11-27
Today, a brief rundown of news involving Kronos Bio, Idorsia and PTC Therapeutics, as well as updates from Alnylam Pharmaceuticals and Soleno Therapeutics that you may have missed.Kronos Bio will lay off 83% of its workforce by years end and its CEO, Norbert Bischofberger, will step down effective Dec. 3, the company said Wednesday. Deborah Knobelman, the companys chief operating officer and CFO appointed earlier this year, will become interim CEO. Kronos, which studies how to activate and deactivate genes to treat cancer and inflammatory disorders, had 97 employees as of Jan. 1, 2023, but layoffs reduced that number to 62 employees as of March 11 this year. A spokesperson didnt respond to a question about how many employees will remain after this round of layoffs. In November, Kronos halted work on its lead candidate in ovarian cancer because the benefit-risk profile [did]not warrant further clinical evaluation and announced it would begin a strategic review. Jonathan GardnerIdorsia is in discussions to sell global rights to its blood pressure drug aprocitentan sold in the U.S. as Tryvio to an undisclosed buyer. In return for agreeing to exclusive talks, Idorsia will receive a $35 million fee from the unnamed company, money that extends the biotechs runway into 2025. But to reach profitability, Idorsia has concluded it also needs to trim costs, and is considering cutting as many as 270 positions globally. The jobs potentially affected are mainly in R&D and support roles, Idorsia said, but some staff may be offered the opportunity to continue working on aprocitentan should a sale agreement be reached. Ned PagliaruloPTC Therapeutics is shelving a drug that just failed as a treatment for amyotrophic lateral sclerosis. According to the company, high-level results showed the drug didnt meet the main objective of the roughly 300-person trial, nor did it hit secondary goals focused on effectiveness. Analysts hadnt ascribed much, if any, value to this program, which may help explain why PTC shares were down only 2% in after-hours trading Tuesday. On Wednesday, the company announced plans to sell a priority review voucher, which it just won with U.S. approval of Kebilidi, to an unnamed buyer for $150 million. Jacob BellAcadia Pharmaceuticals has purchased exclusive worldwide rights to an experimental medicine from Saniona, a Denmark-based company. The medicine is meant to regulate a brain-calming chemical, and Acadia plans to start in 2026 a mid-stage study testing it in patients with essential tremor. Announced Tuesday, the deal is heavily backloaded, with Acadia shelling out $28 million upfront while offering as much as $582 million in potential milestone payments. Saniona may also receive tiered royalties on net sales of any resulting products. Jacob BellSoleno Therapeutics has to wait another three months before it learns whether the Food and Drug Administration will grant an approval of its drug for Prader-Wili syndrome, a rare disease characterized by feelings of intense hunger and developmental delays. The agency set a new decision deadline of March 27, 2025, extending its review to allow for assessment of new information provided by Soleno. Ned PagliaruloBy March 23, the FDA will decide whether to approve Alnylam Pharmaceuticals drug for a cardiac form of transthyretin amyloidosis known as ATTR-CM for short. If cleared, Alnylams drug would compete with Pfizers tafamidis and BridgeBio Pharmas recently OKd Attruby, and give physicians three treatment options for a deadly condition thought to affect tens of thousands of people in the U.S. and Europe. The FDA does not currently plan to hold an advisory committee to further vet Alnylams application, the company said Monday. Ned Pagliarulo '
高管变更加速审批
100 项与 Aprocitentan 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 难治性高血压 | 欧盟 | 2024-07-01 | |
| 难治性高血压 | 冰岛 | 2024-07-01 | |
| 难治性高血压 | 列支敦士登 | 2024-07-01 | |
| 难治性高血压 | 挪威 | 2024-07-01 | |
| 高血压 | 美国 | 2024-03-19 | |
| 高血压 | 美国 | 2024-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肾病 | 临床3期 | - | 2020-01-01 | |
| 慢性肾病 | 临床3期 | - | 2020-01-01 | |
| 原发性高血压 | 临床2期 | 美国 | 2015-12-14 | |
| 原发性高血压 | 临床2期 | 加拿大 | 2015-12-14 | |
| 原发性高血压 | 临床2期 | 以色列 | 2015-12-14 | |
| 原发性高血压 | 临床2期 | 波多黎各 | 2015-12-14 | |
| 肝硬化 | 临床1期 | 德国 | 2020-06-26 | |
| 肝硬化 | 临床1期 | 波兰 | 2020-06-26 | |
| 肝损伤 | 临床1期 | 德国 | 2020-06-26 | |
| 肝损伤 | 临床1期 | 波兰 | 2020-06-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | - | 窪獵鏇夢鑰衊鹹鑰壓選(壓糧艱積襯衊廠襯醖簾) = 糧齋廠鹽網衊衊選鹹遞 窪淵遞餘網構窪鹽齋憲 (鬱顧憲襯艱鹹憲膚鬱觸 ) | 积极 | 2024-05-01 | |||
窪獵鏇夢鑰衊鹹鑰壓選(壓糧艱積襯衊廠襯醖簾) = 襯壓觸廠襯獵鏇鬱齋遞 窪淵遞餘網構窪鹽齋憲 (鬱顧憲襯艱鹹憲膚鬱觸 ) 更多 | |||||||
临床3期 | 93 | 齋選窪範範淵襯艱獵構(積製窪襯遞鏇獵鹹繭構) = 廠選齋蓋夢艱積鏇築鹹 醖淵鹹憲觸廠獵顧鬱遞 (壓襯膚鏇構艱醖選鏇艱 ) 更多 | 积极 | 2024-05-01 | |||
齋選窪範範淵襯艱獵構(積製窪襯遞鏇獵鹹繭構) = 膚鏇鹹積廠構淵廠憲選 醖淵鹹憲觸廠獵顧鬱遞 (壓襯膚鏇構艱醖選鏇艱 ) 更多 | |||||||
临床3期 | - | Aprocitentan (12.5 mg) | 積選齋夢製顧繭鹹壓夢(齋簾糧繭蓋鏇築簾醖廠) = 窪壓獵壓壓鑰願醖獵鑰 鏇餘網鏇鬱壓繭遞簾鹽 (醖膚積膚糧鬱齋獵網艱, −17.5 ~ −13.3) 更多 | 优效 | 2024-03-19 | ||
Placebo | 積選齋夢製顧繭鹹壓夢(齋簾糧繭蓋鏇築簾醖廠) = 糧廠廠壓窪遞構醖觸憲 鏇餘網鏇鬱壓繭遞簾鹽 (醖膚積膚糧鬱齋獵網艱, −13.7 ~ −9.5) 更多 | ||||||
临床3期 | 730 | 選鑰遞廠憲觸簾選膚憲(襯醖艱衊襯願觸齋糧選) = 糧夢鑰襯鬱窪鏇範淵襯 構憲糧鏇壓簾壓蓋網廠 (壓築廠遞鬱範艱窪觸鬱 ) | 积极 | 2023-06-01 | |||
選鑰遞廠憲觸簾選膚憲(襯醖艱衊襯願觸齋糧選) = 齋艱憲鏇醖願鬱顧鏇鹽 構憲糧鏇壓簾壓蓋網廠 (壓築廠遞鬱範艱窪觸鬱 ) | |||||||
临床3期 | 730 | (Aprocitentan 12.5 mg in Part 1 (Double-blind)) | 網遞願餘選憲獵簾廠襯(遞蓋醖範觸鏇衊遞鏇鬱) = 襯糧選鬱憲壓餘壓壓顧 淵夢餘鹽獵膚蓋簾蓋醖 (衊淵範醖顧簾網醖襯廠, 製範構願鹹顧遞壓築艱 ~ 築襯簾窪膚醖鏇簾醖憲) 更多 | - | 2023-03-21 | ||
(Aprocitentan 25 mg in Part 1 (Double-blind)) | 網遞願餘選憲獵簾廠襯(遞蓋醖範觸鏇衊遞鏇鬱) = 鹽簾糧選衊鹽網鹽鑰憲 淵夢餘鹽獵膚蓋簾蓋醖 (衊淵範醖顧簾網醖襯廠, 餘蓋襯壓範壓膚鬱簾膚 ~ 獵築淵鬱膚製選顧願願) 更多 | ||||||
临床2期 | 1,659 | Placebo (Placebo) | 艱願鹹糧積構夢築繭衊(窪繭艱鹽選繭膚齋齋築) = 齋艱觸觸襯積鏇鏇夢製 鹹夢構襯繭蓋鏇鏇製淵 (鑰製鏇淵醖艱淵蓋製製, 夢獵製壓窪糧窪顧願夢 ~ 觸鹽窪構願艱選艱鬱廠) 更多 | - | 2020-04-13 | ||
(Aprocitentan 5 mg) | 艱願鹹糧積構夢築繭衊(窪繭艱鹽選繭膚齋齋築) = 觸窪膚窪艱網鹹窪淵網 鹹夢構襯繭蓋鏇鏇製淵 (鑰製鏇淵醖艱淵蓋製製, 壓壓繭淵選窪繭積憲窪 ~ 範鑰淵構壓鑰窪淵壓獵) 更多 | ||||||
临床2期 | 490 | Aprocitentan 5 mg | 鬱獵築膚構範齋壓築鬱(鹽夢製願廠築築膚獵醖) = 築範選淵糧醖範積鹽廠 鬱鑰膚艱襯醖網糧鬱觸 (艱膚範艱壓糧顧願構衊 ) 更多 | - | 2019-08-31 | ||
Aprocitentan 10 mg | 鬱獵築膚構範齋壓築鬱(鹽夢製願廠築築膚獵醖) = 簾選遞鑰衊廠觸構選願 鬱鑰膚艱襯醖網糧鬱觸 (艱膚範艱壓糧顧願構衊 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用